

# Antiphospholipid syndrome in pregnancy: A controlled treatment trial

<b>Submission date</b> 23/01/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 23/01/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 12/01/2010	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Roy Farquharson

**Contact details**  
Liverpool Women's Hospital  
Crown Street  
Liverpool  
United Kingdom  
L8 7SS  
+44 (0)151 708 9988  
Roy.Farquharson@lwh-tr.nwest.nhs.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
RHC18084

# Study information

## Scientific Title

## Study objectives

To assess the efficacy of low dose heparin in the treatment of antiphospholipid antibody syndrome during pregnancy, comparing low dose aspirin with low dose aspirin combined with low molecular weight heparin, in women suffering from recurring pregnancy loss.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Prevention

## Participant information sheet

## Health condition(s) or problem(s) studied

Pregnancy; antiphospholipid antibody syndrome

## Interventions

1. Aspirin
2. Aspirin and low molecular weight heparin

## Intervention Type

Other

## Phase

Not Specified

## Primary outcome measure

Live birth rate in both arms of the trial (defined as the live birth rate after 24 weeks gestation).

## Secondary outcome measures

The secondary outcome measures will concern maternal morbidity, e.g. osteoporosis, and fetal parameters, such as premature delivery and the incidence for "small for dates".

**Overall study start date**

01/01/1998

**Completion date**

01/01/2000

## Eligibility

**Key inclusion criteria**

Pregnant women with antiphospholipid antibody syndrome

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Female

**Target number of participants**

98 (added 12/01/10; see publication)

**Key exclusion criteria**

Does not match inclusion criteria

**Date of first enrolment**

01/01/1998

**Date of final enrolment**

01/01/2000

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

Liverpool Women's Hospital

Liverpool

United Kingdom

L8 7SS

# Sponsor information

## Organisation

NHS R&D Regional Programme Register - Department of Health (UK)

## Sponsor details

The Department of Health  
Richmond House  
79 Whitehall  
London  
United Kingdom  
SW1A 2NL  
+44 (0)20 7307 2622  
dhmail@doh.gsi.org.uk

## Sponsor type

Government

## Website

<http://www.doh.gov.uk>

# Funder(s)

## Funder type

Government

## Funder Name

NHS Executive North West (UK)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/09/2002		Yes	No